Holen Sie sich die Stockscreener-App
24.54
1.88%
-0.47
Handel nachbörslich:
24.55
0.01
+0.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$25.01
Offen:
$24.62
24-Stunden-Volumen:
28.55M
Relative Volume:
0.71
Marktkapitalisierung:
$139.86B
Einnahmen:
$63.32B
Nettoeinkommen (Verlust:
$7.52B
KGV:
18.81
EPS:
1.3043
Netto-Cashflow:
$9.48B
1W Leistung:
-2.04%
1M Leistung:
+2.08%
6M Leistung:
-4.33%
1J Leistung:
-3.20%
1-Tages-Spanne:
$24.51
$24.75
1-Wochen-Bereich:
$24.51
$25.19
52-Wochen-Spanne:
$23.11
$28.75
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.54 | 139.86B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,196.03 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
263.40 | 634.77B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
259.36 | 458.24B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
131.07 | 323.72B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.01 | 294.63B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Hochstufung | Argus | Hold → Buy |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2026-02-20 | Eingeleitet | Barclays | Underweight |
| 2026-02-12 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-02 | Fortgesetzt | Citigroup | Neutral |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer's Dividend Yield Looks Almost Too Good. Here's Why Management Isn't Worried. - Yahoo Finance
Pfizer's Dividend Yield Looks Almost Too Good. Here's Why Management Isn't Worried. - The Motley Fool
Pfizer stock stabilizes as oncology and vaccine pipeline shapes outlook - AD HOC NEWS
Full Fed. Circ. Urged To Reconsider Pfizer's Paxlovid IP Win - Law360
Pfizer’s ex-comms leader joins Vantage Data Centers - Medical Marketing and Media
Pfizer stock trades steadily as recent earnings and pipeline shape investor sentiment - AD HOC NEWS
How Investors May Respond To Pfizer (PFE) Prostate Cancer Combo Drug Label Expansion Push - simplywall.st
Samsung, Celltrion Join Nectin-4 ADC Race, Challenging Pfizer's Padcev Dominance - finance.biggo.com
Is Pfizer's 7% Dividend Yield Too Good to Be True? Here's the Straight Answer - The Globe and Mail
Pfizer building incident pits banner project with a conversion pitfall - The Real Deal
Pfizer (NYSE:PFE) Leads Healthcare Focus on Balance-Sheet Strength - Kalkine Media
Pfizer stock trades steady as Pfizer India posts stronger FY 2024 earnings - Ad-hoc-news.de
Arkansas Sues Pfizer, J&J, Others Over Drug Discount Access - Bloomberg Law News
Pfizer stock steadies as investors weigh pipeline progress and recent earnings - Ad-hoc-news.de
Pfizer Prevnar 20 by Pfizer Inc.broader adult protection in one syringe - Ad-hoc-news.de
Pfizer Inc (0Q1N) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
What Makes Pfizer (NYSE:PFE) Stand Out in the S&P 500? - Kalkine Media
Pfizer (PFE) Secures Priority Review for Talzenna in Prostate Ca - GuruFocus
Pfizer’s prostate cancer drug combination gets US FDA priority review - 1470 & 100.3 WMBD
Pfizer's prostate cancer drug combination gets US FDA priority review - Reuters
FDA accepts Pfizer filing for Talzenna-Xtandi prostate cancer use - Investing.com
Pfizer trial: TALZENNA combo cut progression-or-death risk 52% - Stock Titan
Bluesight Partners with Pfizer to Integrate SmartDose™ Source-Tagged Medications into KitCheck - HIT Consultant
Pfizer (PFE) Faces New Patent Lawsuits Over Covid 19 Vaccine Technology - simplywall.st
Biogen, Pfizer vet joins Formation Bio as CSO - The Pharma Letter
Pfizer (NYSE:PFE) Oncology Growth Faces A Major Valuation Test - Kalkine Media
Pfizer stock steadies as investors weigh post-COVID revenue mix and pipeline milestones - Ad-hoc-news.de
Sanofi reprimanded for disparaging Pfizer’s RSV vaccine - Fierce Pharma
Prevnar 20 by Pfizerbroader pneumococcal protection for adults - Ad-hoc-news.de
PFE Stock Quote Price and Forecast - CNN
Pfizer (PFE) Stock Seems Fairly Priced As Oncology Approvals Build - simplywall.st
PR News | Pfizer Pro Harnaga Takes Vantage Data PostTue., Jul. 21, 2026 - O'Dwyer's PR
What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season - Yahoo Finance
8 Lessons I’ve Learned as a Cancer Survivor - Pfizer
Tingting Zhang-Kharas Appointed Vice President, Search & Evaluation, Oncology at Pfizer - hrtoday.in
Pfizer building’s collapse scare tests whether New Yorkers will forget and rent anyway - Crain's New York
From Vaccines to Air Traffic: Poland’s Billion-Euro Dispute with Pfizer - finchannel
Pfizer stock trades steady as recent earnings and pipeline updates frame valuation - Ad-hoc-news.de
Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Pfizer Suspends Popular Menopause Cream in India - Benzinga
Axios C-Suite: Pfizer CEO on biotech's China warning - Axios
Pfizer (PFE) Faces New International Patent Lawsuits Over Covid 19 Vaccine - Yahoo Finance
Pfizer stock steadies as investors weigh recent earnings and pipeline progress - Ad-hoc-news.de
Is Trending Stock Pfizer Inc. (PFE) a Buy Now? - Yahoo Finance
Unions seize on Pfizer conversion scare to push for contracts, reforms - The Real Deal
Pfizer site developer’s complex conversion technique draws attention after collapse scare - Crain's New York Business
Pfizer Inc. (PFE) Stock Analysis: Evaluating a 14.92% Potential Upside Amidst Strong Dividend Yield - DirectorsTalk Interviews
Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market? - The Globe and Mail
Lobbying Update: $60,000 of PFIZER lobbying was just disclosed - Quiver Quantitative
Pfizer (NYSE:PFE) shares rise 3.6% on dividend strength as analyst forecasts remain unchanged - TechStock²
Enanta v. Pfizer is Not About a Typo: It is About Possession of the Invention - IPWatchdog.com
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.18%
1.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):